Published in Eur Radiol on December 24, 2010
Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med (2012) 1.34
Dynamic contrast-enhanced MRI of the prostate with high spatiotemporal resolution using compressed sensing, parallel imaging, and continuous golden-angle radial sampling: preliminary experience. J Magn Reson Imaging (2014) 1.05
Feasibility of shutter-speed DCE-MRI for improved prostate cancer detection. Magn Reson Med (2012) 0.96
Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras (2015) 0.92
Cell membrane water exchange effects in prostate DCE-MRI. J Magn Reson (2012) 0.91
The Impact of Arterial Input Function Determination Variations on Prostate Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Modeling: A Multicenter Data Analysis Challenge. Tomography (2016) 0.89
Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol (2012) 0.88
Percutaneous MR-guided cryoablation of prostate cancer: initial experience. Eur Radiol (2012) 0.88
PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer. Contemp Clin Trials (2015) 0.87
Visualization, imaging and new preclinical diagnostics in radiation oncology. Radiat Oncol (2014) 0.86
Is it possible to model the risk of malignancy of focal abnormalities found at prostate multiparametric MRI? Eur Radiol (2012) 0.85
A simulation tool for dynamic contrast enhanced MRI. PLoS One (2013) 0.84
Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. Eur Radiol (2015) 0.84
An open source software for analysis of dynamic contrast enhanced magnetic resonance images: UMMPerfusion revisited. BMC Med Imaging (2016) 0.84
Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging. Eur Radiol (2014) 0.83
Prostate focused ultrasound focal therapy--imaging for the future. Nat Rev Clin Oncol (2012) 0.83
Differentiation of myeloma and metastatic cancer in the spine using dynamic contrast-enhanced MRI. Magn Reson Imaging (2013) 0.82
Correlation between dynamic contrast-enhanced MRI and quantitative histopathologic microvascular parameters in organ-confined prostate cancer. Eur Radiol (2014) 0.81
Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know? Eur Radiol (2012) 0.79
IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. AJR Am J Roentgenol (2015) 0.77
Improved performance of prostate DCE-MRI using a 32-coil vs. 12-coil receiver array. Magn Reson Imaging (2017) 0.75
The value of dynamic contrast-enhanced MRI in characterizing complex ovarian tumors. J Ovarian Res (2017) 0.75
Dynamic Contrast-Enhanced MRI in the Study of Brain Tumors. Comparison Between the Extended Tofts-Kety Model and a Phenomenological Universalities (PUN) Algorithm. J Digit Imaging (2015) 0.75
Diagnostic value of dynamic contrast-enhanced magnetic resonance imaging in rectal cancer and its correlation with tumor differentiation. Mol Clin Oncol (2016) 0.75
Applications of imaging technology in radiation research. Radiat Res (2012) 0.75
[Focal therapy of prostate cancer]. Urologe A (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med (1991) 5.33
Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med (2006) 3.63
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Microvascular permeability of normal and neoplastic tissues. Microvasc Res (1986) 3.04
Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg (1966) 3.00
Imaging prostate cancer: a multidisciplinary perspective. Radiology (2007) 2.79
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol (2006) 2.44
Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg (2008) 2.39
Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr (1991) 2.34
Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology (2003) 2.31
Serial biopsy results in prostate cancer screening study. J Urol (2002) 2.30
Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR (1984) 2.30
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol (1994) 2.25
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology (2004) 2.13
Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med (1995) 2.10
Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol (2009) 2.01
Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med (2006) 1.93
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance. Radiology (2007) 1.92
Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92
Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging (2007) 1.90
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology (2007) 1.72
Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology (2006) 1.69
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. Radiology (2007) 1.67
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med (1995) 1.65
Placental perfusion and permeability: simultaneous assessment with dual-echo contrast-enhanced MR imaging in mice. Radiology (2006) 1.60
Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR imaging. Radiology (1993) 1.60
Theory of the measurement of blood flow by the dilution of an indicator. Bull Math Biophys (1948) 1.49
Functional MR imaging of prostate cancer. Radiographics (2007) 1.48
Morphologic and hemodynamic comparison of tumor and healing normal tissue microvasculature. Int J Radiat Oncol Biol Phys (1989) 1.39
Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology (2004) 1.36
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol (2006) 1.32
Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol (1993) 1.31
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: technique and feasibility. Invest Radiol (2008) 1.26
Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology (1989) 1.26
Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol (2009) 1.26
Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging (2001) 1.25
Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol (2008) 1.20
Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med (2001) 1.19
Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology (2002) 1.19
Measurement of the arterial concentration of Gd-DTPA using MRI: a step toward quantitative perfusion imaging. Magn Reson Med (1996) 1.19
Topography of neovascularity in human prostate carcinoma. Cancer (1995) 1.18
Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol (2009) 1.18
Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer (1999) 1.16
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed (2002) 1.16
Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. Eur Radiol (2006) 1.15
Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging (1999) 1.14
Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. J Magn Reson Imaging (2001) 1.12
Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology (1999) 1.11
Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.10
Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology (2001) 1.10
Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol (2003) 1.08
An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: II. Experimental validation. J Cereb Blood Flow Metab (1998) 1.06
Prostate MR imaging: tissue characterization with pharmacokinetic volume and blood flow parameters and correlation with histologic parameters. Radiology (2009) 1.04
Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol (2009) 1.03
Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol (2010) 1.02
Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings. Urology (2004) 1.01
Precision in measurements of perfusion and microvascular permeability with T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med (2006) 1.00
Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol (2008) 0.99
Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol (2000) 0.96
Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy. Eur Radiol (2008) 0.96
Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys (2001) 0.96
Reference tissue quantification of DCE-MRI data without a contrast agent calibration. Phys Med Biol (2007) 0.95
Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. Int J Radiat Oncol Biol Phys (2009) 0.94
Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer (2004) 0.92
Artifacts and pitfalls in MR imaging of the pelvis. J Magn Reson Imaging (2007) 0.92
Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol (2008) 0.91
Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence. Ann Biomed Eng (2009) 0.90
The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol (1995) 0.90
Molecular markers and mortality in prostate cancer. BJU Int (2007) 0.89
MRI of prostate cancer at 1.5 and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol (2005) 0.88
Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev (2001) 0.87
Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother (2010) 0.86
Imaging for recurrent prostate cancer. Radiol Clin North Am (2000) 0.85
[Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography]. Radiologe (1997) 0.84
Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol (2004) 0.84
The importance of correct norms in blood volume measurement. Am J Med Sci (2007) 0.83
Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol (2001) 0.81
Implementation of a rapid inversion-prepared dual-contrast gradient echo sequence for quantitative dynamic contrast-enhanced magnetic resonance imaging of the human prostate. Magn Reson Imaging (2005) 0.81
[Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer]. Rofo (2009) 0.79
A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2003) 0.78
Accelerated parallel imaging by transform coding data compression with k-t SENSE. Conf Proc IEEE Eng Med Biol Soc (2006) 0.78
Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Magn Reson Imaging (2006) 0.75
Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: "love the one you're with" and "do the right thing". Int J Radiat Oncol Biol Phys (2003) 0.75
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Improving communication of diagnostic radiology findings through structured reporting. Radiology (2011) 2.69
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology (2005) 2.49
Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation (2008) 2.41
Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology (2006) 2.40
A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum (2005) 2.36
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology (2009) 2.24
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology (2004) 2.16
Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology (2004) 2.13
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology (2011) 2.10
Noninvasive detection of coronary artery stenoses with multislice computed tomography or magnetic resonance imaging. Ann Intern Med (2006) 2.04
Head-to-head comparison of left ventricular function assessment with 64-row computed tomography, biplane left cineventriculography, and both 2- and 3-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging as the reference standard. J Am Coll Cardiol (2012) 1.90
Solid renal cortical tumors: differentiation with CT. Radiology (2007) 1.87
Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80
Rheumatoid arthritis of the shoulder joint: comparison of conventional radiography, ultrasound, and dynamic contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2003) 1.79
Radiation exposure from medical imaging: time to regulate? JAMA (2010) 1.74
Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study. Radiology (2012) 1.74
Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology (2007) 1.72
Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. J Clin Oncol (2006) 1.71
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology (2004) 1.69
Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology (2006) 1.69
Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology (2002) 1.68
Renal masses: characterization with diffusion-weighted MR imaging--a preliminary experience. Radiology (2008) 1.67
Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol (2012) 1.64
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol (2011) 1.63
Blood loss during radical retropubic prostatectomy: relationship to morphologic features on preoperative endorectal magnetic resonance imaging. Urology (2002) 1.61
Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2011) 1.59
Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology (2006) 1.57
Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Radiology (2008) 1.56
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer (2004) 1.55
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
Does ultra-low-dose CT with a radiation dose equivalent to that of KUB suffice to detect renal and ureteral calculi? J Comput Assist Tomogr (2005) 1.54
Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. AJR Am J Roentgenol (2003) 1.53
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res (2005) 1.53
Comparison of non-gated vs. electrocardiogram-gated 64-detector-row computed tomography for integrated electroanatomic mapping in patients undergoing pulmonary vein isolation. Europace (2010) 1.50
Imaging of transposed ovaries in patients with cervical carcinoma. AJR Am J Roentgenol (2005) 1.49
Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging (2008) 1.48
Viscoelasticity-based staging of hepatic fibrosis with multifrequency MR elastography. Radiology (2010) 1.45
Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol (2005) 1.42
Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient. Radiology (2013) 1.42
Triage of patients with suspected coronary artery disease using multislice computed tomography. Acad Radiol (2007) 1.41
Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology (2008) 1.39
Urinary continence after radical retropubic prostatectomy: relationship with membranous urethral length on preoperative endorectal magnetic resonance imaging. J Urol (2002) 1.39
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology (2002) 1.37
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl Med (2008) 1.35
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol (2005) 1.35
Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results. Radiology (2003) 1.33
Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys (2007) 1.31
Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology (2005) 1.30
Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology (2004) 1.30
Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics (2004) 1.29
Molecular imaging for personalized cancer care. Mol Oncol (2012) 1.28
Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis. Radiology (2005) 1.27
Imaging appearance of granulomatous disease after intravesical Bacille Calmette-Guerin (BCG) treatment of bladder carcinoma. AJR Am J Roentgenol (2009) 1.27
Multisegment and halfscan reconstruction of 16-slice computed tomography for detection of coronary artery stenoses. Invest Radiol (2004) 1.26
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU Int (2011) 1.26
Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology (2006) 1.24
Real-time sonoelastography performed in addition to B-mode ultrasound and mammography: improved differentiation of breast lesions? Acad Radiol (2006) 1.23
Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology (2004) 1.21
Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology (2002) 1.19
Cost effectiveness of coronary angiography and calcium scoring using CT and stress MRI for diagnosis of coronary artery disease. Eur Radiol (2006) 1.19
Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol (2004) 1.18
Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: initial experience in humans. J Magn Reson Imaging (2011) 1.18
Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization. Int J Nanomedicine (2013) 1.17
Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol (2002) 1.17
Cardiac magnetic resonance elastography. Initial results. Invest Radiol (2008) 1.17
Semi-automatic deformable registration of prostate MR images to pathological slices. J Magn Reson Imaging (2010) 1.17
Evaluation of global and regional left ventricular function with 16-slice computed tomography, biplane cineventriculography, and two-dimensional transthoracic echocardiography: comparison with magnetic resonance imaging. J Am Coll Cardiol (2006) 1.17
Haralick texture analysis of prostate MRI: utility for differentiating non-cancerous prostate from prostate cancer and differentiating prostate cancers with different Gleason scores. Eur Radiol (2015) 1.16
Spinal changes in patients with spondyloarthritis: comparison of MR imaging and radiographic appearances. Radiographics (2005) 1.16
MR imaging of the prostate in clinical practice. MAGMA (2008) 1.15
Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology (2009) 1.14
Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology (2006) 1.14
Intra- and interobserver variability in CT measurements in oncology. Radiology (2013) 1.14
Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol (2011) 1.13
MR imaging of treated prostate cancer. Radiology (2012) 1.13
Diffusion-weighted echo-planar magnetic resonance imaging for the assessment of tumor cellularity in patients with soft-tissue sarcomas. J Magn Reson Imaging (2009) 1.13
Cardiac MR elastography: comparison with left ventricular pressure measurement. J Cardiovasc Magn Reson (2009) 1.13
18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med (2007) 1.12
Computed tomography for preoperative planning in minimal-invasive total hip arthroplasty: radiation exposure and cost analysis. Eur J Radiol (2009) 1.12
Digital mammography using iodine-based contrast media: initial clinical experience with dynamic contrast medium enhancement. Invest Radiol (2005) 1.10
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene. Clin Cancer Res (2009) 1.10
Imaging of prostate cancer. Radiol Clin North Am (2007) 1.09
Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations. Radiology (2004) 1.09
Magnetic resonance imaging of active sacroiliitis: do we really need gadolinium? Eur J Radiol (2009) 1.08
Evaluation of the prostate imaging reporting and data system for the detection of prostate cancer by the results of targeted biopsy of the prostate. Invest Radiol (2014) 1.08
Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin Cancer Res (2008) 1.07
Magnetic resonance imaging-targeted prostate biopsies: now is the time to START. Eur Urol (2013) 1.07
Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology (2007) 1.07
Epidural venous enlargements presenting with intractable lower back pain and sciatica in a patient with absence of the infrarenal inferior vena cava and bilateral deep venous thrombosis. Spine (Phila Pa 1976) (2007) 1.06
Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. Abdom Imaging (2015) 1.06
Non-cardiac findings on coronary computed tomography and magnetic resonance imaging. Eur Radiol (2007) 1.06